Molecular pathology laboratories need to provide prompt assessments of the molecular biomarkers present in tumor samples to allow informed treatment decisions. AuraSeq uses next-generation sequencing (NGS) technology enabling the testing of multiple biomarkers, such as somatic variants in oncogenic driver genes, in a single assay.
For further information, please contact:
Jorge Almenara, Ph.D.
Strategic Accounts Manager
Acting General Manager for Bernhardt Laboratories
Reference: Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.